Gennex Laboratories Limited share price
BSE: GENNEX
Key numbers
- Market cap
- ₹ 245 Cr
- Current price
- ₹ 10.10
- 52-week high / low
- ₹ 17 / 7
- Stock P/E
- 12.0
- Book value
- ₹ 9.2
- Dividend yield
- 0.00%
- ROCE
- 10.9%
- ROE
- 10.3%
- Debt to equity
- 0.36
- Sales growth (3 yrs)
- 38.5%
- Profit growth (3 yrs)
- 62.2%
- 1-year return
- -19.9%
About Gennex Laboratories Limited
Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin; and Allopurinol, a xanthine oxidase inhibitor. It has operations in India, Algeria, Bangladesh, Barzil, Bolivia, Colombia, the Czech Republic, Egypt, El Salvador, Germany, Guatemala City, Mexico, Peru, Spain, Turkey, Thailand, the United Arab Emirates, and Vietnam. Gennex Laboratories Limited was formerly known as Prudential Pharmaceuticals Limited and changed its name to Gennex Laboratories Limited in September 2007. Gennex Laboratories Limited was incorporated in 1985 and is based in Hyderabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 34 | 37 | 40 | 61 | 40 |
| Operating profit | 5 | 8 | 9 | 6 | 4 |
| Net profit | 5 | 5 | 5 | 4 | 5 |
| EPS (₹) | 0.22 | 0.21 | 0.22 | 0.16 | 0.19 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.